Prevention and prediction in Diabetes Mellitus type 1
DOI:
https://doi.org/10.47196/diab.v53i2Sup.228Keywords:
diabetes, preventionAbstract
Type 1 diabetes mellitus (DM1) is a disease characterized by the autoimmune destruction of the beta cell mediated by the attack of cytotoxic T lymphocytes and in which the autoantibodies (GADA, IAA, AI2A and ZnT8A) are markers of it. Since this disease has polygenic bases, the risk of developing DM1 is more frequent in first-degree relatives than in the general population.
References
- Skyler JS. Primary and secondary prevention of type 1 diabetes. Diabet Med 2013; 30: 161-169.
- Ziegler AG, Rewers M, Simell O, et al. Seroconversion to multiple islet autoantibodies and risk of progression to diabetes in children. JAMA 2013; 309: 2473-2479.
- Jacobsen LM, Haller MJ, Schatz DA. Understanding pre-type 1 diabetes: the key to prevention. Frontiers in Endocrinology 2018; 9:70. Doi: 10.3389/fendo.2018.00070.
- Herold KC, Bundy BN, Long A, et al. An anti-CD3 antibody, teplizumab, in relatives at risk for type 1 diabetes. N Engl J Med 2019 Jun 9. Doi: 10.1056/NEJMoa1902226.
Downloads
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Dirección Nacional de Derecho de Autor, Exp. N° 5.333.129. Instituto Nacional de la Propiedad Industrial, Marca «Revista de la Sociedad Argentina de Diabetes - Asociación Civil» N° de concesión 2.605.405 y N° de disposición 1.404/13.
La Revista de la SAD está licenciada bajo Licencia Creative Commons Atribución – No Comercial – Sin Obra Derivada 4.0 Internacional.
Por otra parte, la Revista SAD permite que los autores mantengan los derechos de autor sin restricciones.
